Patents by Inventor Zhenming AN

Zhenming AN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VARIANTS OF ETANERCEPT AND RELATED PROCESSES
    Publication number: 20260159569
    Abstract: The present disclosure relates to variants of etanercept and related processes. The variants are specific truncation variants of etanercept. Also provided herein are a pharmaceutical formulation comprising the variants. Additionally, provided herein is a method for decreasing the variants. The method can effectively optimize the amount of the truncation variants, with simplicity in process and ease in operation.
    Type: Application
    Filed: February 25, 2025
    Publication date: June 11, 2026
    Applicant: QILU PHARMACEUTICAL CO., LTD.
    Inventors: Bo SUN, Guodong JIA, Zhenming AN, Ming LIN, Songhuan WEI, Shouyu ZHANG, Tingting XING, Hai LI, Yanfeng ZHU
  • COMPOSITION COMPRISING AFLIBERCEPT AND A VARIANT THEREOF, AND RELATED METHODS AND USES
    Publication number: 20260103739
    Abstract: Provided is a composition comprising aflibercept and a variant thereof, wherein the variant is a truncation variant with a truncated VEGF binding portion of aflibercept, and wherein the content of the truncation variant is less than or equal to about 20% by mass percentage. Also provided is a pharmaceutical formulation comprising the composition, and a method for preparing the same. Further, provided are a method for detecting the variant and use of the variant in quality inspection or quality control of an aflibercept-containing product.
    Type: Application
    Filed: December 11, 2025
    Publication date: April 16, 2026
    Applicant: Qilu Pharmaceutical Co., LTD.
    Inventors: Bo PAN, Yue YU, Guijiang WANG, Jianmin FAN, Jiulin WANG, Zhenming AN, Qingmin WANG, Daoyuan LI, Jianjun ZHANG, Chuanlei LIU, Feifei LIU, Huanlan ZHENG, Peng WAN, Bo XIE
  • Composition comprising aflibercept and a variant thereof, and related methods and uses
    Patent number: 12540345
    Abstract: Provided is a composition comprising aflibercept and a variant thereof, wherein the variant is a truncation variant with a truncated VEGF binding portion of aflibercept, and wherein the content of the truncation variant is less than or equal to about 20% by mass percentage. Also provided is a pharmaceutical formulation comprising the composition, and a method for preparing the same. Further, provided are a method for detecting the variant and use of the variant in quality inspection or quality control of an aflibercept-containing product.
    Type: Grant
    Filed: March 19, 2025
    Date of Patent: February 3, 2026
    Assignee: Qilu Pharmaceutical Co., LTD.
    Inventors: Bo Pan, Yue Yu, Guijiang Wang, Jianmin Fan, Jiulin Wang, Zhenming An, Qingmin Wang, Daoyuan Li, Jianjun Zhang, Chuanlei Liu, Feifei Liu, Huanlan Zheng, Peng Wan, Bo Xie
  • A COMPOSITION COMPRISING AFLIBERCEPT AND A VARIANT THEREOF, AND RELATED METHODS AND USES
    Publication number: 20250346937
    Abstract: Provided is a composition comprising aflibercept and a variant thereof, wherein the variant is a truncation variant with a truncated VEGF binding portion of aflibercept, and wherein the content of the truncation variant is less than or equal to about 20% by mass percentage. Also provided is a pharmaceutical formulation comprising the composition, and a method for preparing the same. Further, provided are a method for detecting the variant and use of the variant in quality inspection or quality control of an aflibercept-containing product.
    Type: Application
    Filed: March 19, 2025
    Publication date: November 13, 2025
    Applicant: Qilu Pharmaceutical Co., LTD.
    Inventors: Bo PAN, Yue YU, Guijiang WANG, Jianmin FAN, Jiulin WANG, Zhenming AN, Qingmin WANG, Daoyuan LI, Jianjun ZHANG, Chuanlei LIU, Feifei LIU, Huanlan ZHENG, Peng WAN, Bo XIE
  • COMPOSITION COMPRISING AFLIBERCEPT AND A VARIANT THEREOF, AND RELATED METHODS AND USES
    Publication number: 20250333478
    Abstract: Provided is a composition comprising aflibercept and a variant thereof, wherein the variant is a truncation variant with a truncated VEGF binding portion of aflibercept, and wherein the content of the truncation variant is less than or equal to about 20% by mass percentage. Also provided is a pharmaceutical formulation comprising the composition. Further, provided are a method for detecting the variant and use of the variant in quality inspection or quality control of an aflibercept-containing product.
    Type: Application
    Filed: December 4, 2024
    Publication date: October 30, 2025
    Inventors: Yue YU, Guijiang WANG, Jiulin WANG, Zhenming AN, Qingmin WANG, Daoyuan LI, Chuanlei LIU, Feifei LIU, Huanlan ZHENG, Peng WAN, Bo XIE
  • Antibody against claudin 18A2 and use thereof
    Patent number: 12415853
    Abstract: Provided are an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, a derivative comprising said antibody or antigen-binding fragment thereof, a pharmaceutical composition, and related use of said antibody or antigen-binding fragment thereof for treating, diagnosing and detecting cancers.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: September 16, 2025
    Assignee: QILU PHARMACEUTICAL CO., LTD.
    Inventors: Yingying Yang, Gao Li, Yaning Wang, Zhenming An, Shuyong Zhao, Yuxue Liu, Shicong Liu, Meijuan Zhang, Jinjin Jiang
  • Composition comprising aflibercept and a variant thereof, and related methods and uses
    Patent number: 12240888
    Abstract: Provided is a composition comprising aflibercept and a variant thereof, wherein the variant is a truncation variant with a truncated VEGF binding portion of aflibercept, and wherein the content of the truncation variant is less than or equal to about 20% by mass percentage. Also provided is a pharmaceutical formulation comprising the composition. Further, provided are a method for detecting the variant and use of the variant in quality inspection or quality control of an aflibercept-containing product.
    Type: Grant
    Filed: May 30, 2024
    Date of Patent: March 4, 2025
    Assignee: QILU Pharmaceutical, Co., Ltd.
    Inventors: Yue Yu, Guijiang Wang, Jiulin Wang, Zhenming An, Qingmin Wang, Daoyuan Li, Chuanlei Liu, Feifei Liu, Huanlan Zheng, Peng Wan, Bo Xie
  • ANTIBODY AGAINST CLAUDIN 18A2 AND USE THEREOF
    Publication number: 20220411492
    Abstract: Provided are an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, a derivative comprising said antibody or antigen-binding fragment thereof, a pharmaceutical composition, and related use of said antibody or antigen-binding fragment thereof for treating, diagnosing and detecting cancers.
    Type: Application
    Filed: May 15, 2020
    Publication date: December 29, 2022
    Applicant: QILU PHARMACEUTICAL CO., LTD.
    Inventors: Yingying YANG, Gao LI, Yaning WANG, Zhenming AN, Shuyong ZHAO, Yuxue LIU, Shicong LIU, Meijuan ZHANG, Jinjin JIANG